GSK plc

Equities

GSK

GB00BN7SWP63

Pharmaceuticals

Real-time Estimate Cboe Europe 04:29:21 2024-09-18 am EDT 5-day change 1st Jan Change
1,599.50 GBX -0.62% Intraday chart for GSK plc -3.17% +10.47%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
European Equities Traded in the US as American Depositary Receipts Edge Lower in Tuesday Trading MT
GSK: Japan agrees to review Blenrep application CF
GSK : JP Morgan remains a Sell rating ZD
GSK says Blenrep combinations accepted for review in Japan AN
GSK's Blood Cancer Treatment Application Accepted for Review in Japan MT
GSK PLC : Despite transitioning towards speciality pharma, GSK is trading at OTC prices Alphavalue
ITeos Therapeutics Shares Rise on Positive Data From Lung Cancer Study DJ
GSK : Goldman Sachs gives a Neutral rating ZD
Moderna's Faces 'Material Headwinds' on RSV, COVID, RBC Says MT
GSK Bets on Blood-Cancer Drug Comeback Amid Oncology Push DJ
European Equities Close Higher on Friday; HSBC Mulls Potential Sale of South African Unit MT
GSK Says Blenrep Granted Breakthrough Therapy Designation in China MT
GSK: innovative therapy designation granted in China CF
GSK : Goldman Sachs reaffirms its Neutral rating ZD
GSK myeloma treatment given breakthrough therapy designation in China AN
GSK's Plasma Cell Cancer Treatment Receives Breakthrough Designation in China MT
European Equities Close Higher in Thursday Trading; European Central Bank Cuts Rates by 25 Basis Points MT
ECB to cut rates without lowering its guard Our Logo
GSK Reports Positive Resuts in Trial of mRNA Influenza Vaccine MT
GSK plc Announces Positive Headline Results of A Phase Ii Trial (Nct06431607) for Its Mrna Seasonal Influenza Vaccine Programme CI
GSK: positive results for influenza vaccine CF
GSK welcomes positive findings on possible flu treatment AN
British drugmaker GSK moves mRNA flu vaccine to late-stage trials RE
GSK's mRNA Flu Vaccine Advances to Late-Stage Clinical Development After Positive Trial Results DJ
Trainline lifts guidance; Kier Group earnings climb AN
Chart GSK plc
More charts
Logo GSK plc
GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Employees
70,212
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
16.10GBP
Average target price
19.68GBP
Spread / Average Target
+22.27%
Consensus
  1. Stock Market
  2. Equities
  3. GSK Stock
  4. News GSK plc
  5. US FDA Expands Approval of GSK's Endometrial Cancer Treatment Jemperli
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW